Tradestie Institutional Equity Comparison Engine
CURE vs TECL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CURE Overall Edge
CURE Captures Institutional Edge (1โ1 Pillars ยท 2โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Direxion Daily Healthcare Bull 3X Shares (CURE) driven by superior Momentum & Technical while TECL counters with relative strength in Options & Structure. Fundamentally, CURE trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus TECL at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CURE sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against TECL sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CURE N/M vs TECL N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner
CURE
1Y +61.2% vs +1.3% ยท 52W Pos 88% vs 26%
Options & Structure Winner
TECL
UNCLASSIFIED (9th %ile IV) vs BREAKDOWN (6th %ile IV)
CURE
NYSE Arca
Direxion Daily Healthcare Bull 3X Shares
Institutional Equity
$174.60
-1.57% 1D
Market Cap
N/A
1M Return
+18.16%
1Y Return
+61.19%
Forward P/E
N/M
Unified AI Score
38.6 / 100
SELL
Tech 15.0
Fund 27.0
Flow 50.0
Mom 36.3
TECL
NYSE Arca
Direxion Daily Technology Bull 3x Shares
Institutional Equity
$127.76
-9.81% 1D
Market Cap
N/A
1M Return
-32.3%
1Y Return
+1.33%
Forward P/E
N/M
Unified AI Score
52.1 / 100
HOLD
Tech 43.0
Fund 53.0
Flow 58.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CURE +61.19%
TECL +1.33%
Spread: +59.86 pp (CURE Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CURE TTM Op. Margin: N/A
TECL TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CURE vs TECL. Trailing 12-month operating profitability (CURE N/A vs TECL N/A) and valuation multiples (CURE N/M vs TECL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CURE | TECL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | N/A | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | N/A | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | N/A | N/A | Higher Margin | Tie |
| Net Profit Margin Profitability | N/A | N/A | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | N/A | N/A | Higher ROE | Tie |
| 52-Week Range Position Momentum | 88% ($82โ$188) | 26% ($75โ$275) | Stronger Trend | CURE |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 62% Vol | 5.46ฮฒ ยท 133% Vol | Lower Realized Risk | CURE |
| Unified Institutional Score Composite Signal | 38.6 / 100 (SELL) | 52.1 / 100 (HOLD) | Higher Composite | TECL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CURE vs TECL Buy Guide
CURE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
TECL
BREAKDOWN
116d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CURE nor TECL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.